Search by conditions:

 

Protocol Description Phase
16-517 A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR Study)  (View details on clinicaltrial.gov) Phase III
16-030 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)  (View details on clinicaltrial.gov) Phase II
14-135 A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor(FGF/FGFR)- Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma FGF/FGFR-Related Abnormalities  (View details on clinicaltrial.gov) Phase II
17-521 A Double-Blind, Placebo-Controlled, Randomized, Phase III Study of Ipataserib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase III
14-004 A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastroesophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer  (View details on clinicaltrial.gov) Phase I
14-537 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov) Phase I
14-389 A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)  (View details on clinicaltrial.gov) Phase I
16-301 A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Refractory Metastatic Anal Cancer  (View details on clinicaltrial.gov) Phase II
15-398 A Multicenter Phase II Clinical Trial of Lubrinectedin (PM01183) In Selected Advanced Solid Tumors.  (View details on clinicaltrial.gov) Phase II
15-497 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  (View details on clinicaltrial.gov) Phase II
17-274 A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD)  (View details on clinicaltrial.gov) N/A
16-377 A Multicenter, Open-label, Phase 1B Clinical Study of CMP-001 in combination with Pembrolizumab in Subjects with Advanced Melanoma  (View details on clinicaltrial.gov) Phase I
17-018 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-438 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-421 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  (View details on clinicaltrial.gov) Phase III
17-124 A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib +Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer.  (View details on clinicaltrial.gov) Phase III
17-193 A Multicentre, Randomized, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr Virusspecific Autologous Cytotoxic T Lymphocytes versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients  (View details on clinicaltrial.gov) Phase III
17-736 A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma  (View details on clinicaltrial.gov) Phase II
17-607 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-392 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-393 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-421 A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects with Relapsed or Refractory B-Cell Non-Hodgkins's Lymphoma  (View details on clinicaltrial.gov) Phase I
15-522 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
15-446 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and pharmacodynamics of AMG 224 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
17-551 A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects with Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
17-184 A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activityof MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancies  (View details on clinicaltrial.gov) Phase I
17-188 A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-456 A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination with Other Agents in Advanced Cancer  (View details on clinicaltrial.gov) Phase I
17-379 A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
17-718 A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia  (View details on clinicaltrial.gov) Phase I
17-241 A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity  (View details on clinicaltrial.gov) Phase I
16-359 A phase 1 study of SGN-CD123A in patients with relapsed or refractory acute myeloid leukemia (AML)  (View details on clinicaltrial.gov) Phase I
17-236 A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-285 A phase 1 study of the CDK4/6 inhibitor ribociclib (LEE011) in combination with the PD-1 inhibitor PDR001 in patients with metastatic hormone receptor-positive breast cancer and metastatic ovarian cancer  (View details on clinicaltrial.gov) Phase I
17-002 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-076 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase I
17-634 A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-186 A Phase 1, First-In-Human, Multi-Part Study of RAD140 in Postmenopausal Women Hormone Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
14-524 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma  (View details on clinicaltrial.gov) Phase I
16-510 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov) Phase I
15-404 A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)  (View details on clinicaltrial.gov) Phase I
15-527 A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation  (View details on clinicaltrial.gov) Phase I
11-217 A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fcoptimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov) Phase I
16-534 A Phase 1, Open-Label, Dose Escalation Study of Intravenous Administration of Single Agent BTP-114 in Patients with Advanced Solid Tumors and a Known Deleterious BRCA or DNA Repair Mutation  (View details on clinicaltrial.gov) Phase I
16-611 A Phase 1, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-330 A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-229 A Phase 1, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects with High Risk (IPI 3 Or More) Previously Untreated Diffuse Large B-Cell Lymphoma or Grade 3B Follicular Lymphoma  (View details on clinicaltrial.gov) Phase I
17-334 A Phase 1, Open-Label, Multicenter, Dose Escalation Study or MRNA-2416, A Lipid Nanoparticle Encapsulated MRNA Encoding Human OX4OL, For Intratumoral Injection to Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
17-288 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult patients with advanced solid tumors  (View details on clinicaltrial.gov) Phase I
16-008 A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-308 A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase I
16-526 A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer  (View details on clinicaltrial.gov) Phase I
15-207 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma  (View details on clinicaltrial.gov) Phase II
15-471 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D)in Subjects with Advanced Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-242 A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia  (View details on clinicaltrial.gov) Phase II
17-371 A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer  (View details on clinicaltrial.gov) Phase II
15-576 A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
16-143 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
16-379 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase II
16-586 A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors  (View details on clinicaltrial.gov) Phase II
16-450 A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advanced cancers, including gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung.  (View details on clinicaltrial.gov) Phase II
17-240 A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer  (View details on clinicaltrial.gov) Phase I
16-154 A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma  (View details on clinicaltrial.gov) Phase I
17-187 A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure  (View details on clinicaltrial.gov) Phase I
16-714 A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor  (View details on clinicaltrial.gov) Phase I
16-132 A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)  (View details on clinicaltrial.gov) Phase I
17-328 A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pembrolizumab in HLA-A2+ Patients with Metastatic Triple Negative Breast Cancer (TNBC)  (View details on clinicaltrial.gov) Phase I
14-539 A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
16-395 A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-505 A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin or Pembrolizumab in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer  (View details on clinicaltrial.gov) Phase I
16-472 A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2  (View details on clinicaltrial.gov) Phase I
17-243 A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)  (View details on clinicaltrial.gov) Phase I
17-157 A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary Embolism  (View details on clinicaltrial.gov) Phase I
16-057 A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy  (View details on clinicaltrial.gov) Phase II
16-399 A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
17-435 A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma  (View details on clinicaltrial.gov) Phase II
17-687 A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS  (View details on clinicaltrial.gov) Phase II
15-343 A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
16-258 A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer  (View details on clinicaltrial.gov) Phase II
15-322 A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma  (View details on clinicaltrial.gov) Phase II
14-332 A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma  (View details on clinicaltrial.gov) Phase II
17-429 A Phase 1b/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer)  (View details on clinicaltrial.gov) Phase II
16-493 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies  (View details on clinicaltrial.gov) Phase II
17-499 A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer  (View details on clinicaltrial.gov) Phase II
16-383 A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
16-019 A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor  (View details on clinicaltrial.gov) Phase II
17-291 A Phase 2 Study of EGF816 and gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
17-044 A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer  (View details on clinicaltrial.gov) Phase II
16-308 A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
15-295 A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-566 A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
16-220 A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), In Patients with Advanced Cutaneous Squamous Cell Carcinoma  (View details on clinicaltrial.gov) Phase II
17-173 A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis  (View details on clinicaltrial.gov) Phase II
16-505 A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia  (View details on clinicaltrial.gov) Phase II
17-084 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)  (View details on clinicaltrial.gov) Phase II
16-239 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)  (View details on clinicaltrial.gov) Phase II
17-652 A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
16-069 A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia  (View details on clinicaltrial.gov) Phase II
17-454 A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)  (View details on clinicaltrial.gov) Phase II
16-340 A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)  (View details on clinicaltrial.gov) Phase II
16-296 A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer  (View details on clinicaltrial.gov) Phase II
15-571 A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency  (View details on clinicaltrial.gov) Phase II
16-322 A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients with MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer  (View details on clinicaltrial.gov) Phase II
16-171 A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)  (View details on clinicaltrial.gov) Phase III
14-059 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07  (View details on clinicaltrial.gov) Phase III
17-304 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase III
16-302 A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy  (View details on clinicaltrial.gov) Phase III
17-114 A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase III
17-397 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma  (View details on clinicaltrial.gov) Phase III
17-137 A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer.  (View details on clinicaltrial.gov) Phase I
12-283 A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
17-033 A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC)  (View details on clinicaltrial.gov) Phase I
06-068 A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on clinicaltrial.gov) Phase I
13-581 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Previously Treated Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
17-586 A PHASE I STUDY OF DS-3201B IN SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR ACUTE LYMPHOCYTIC LEUKEMIA (ALL)  (View details on clinicaltrial.gov) Phase I
15-467 A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma  (View details on clinicaltrial.gov) Phase I
12-306 A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients  (View details on clinicaltrial.gov) Phase I
16-726 A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor  (View details on clinicaltrial.gov) Phase I
16-626 A Phase I Trial of CBT-1® in Combination with Doxorubicin in Patients with Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or less of Doxorubicin  (View details on clinicaltrial.gov) Phase I
15-023 A Phase I Trial Of Intensity-modulated Radiation Therapy Using A Contralateral Esophagus Sparing Technique In Locally Advanced Non-Small Cell Lung Cancer and Limited-Stage Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov) Phase I
15-417 A Phase I, Multicenter, Open-Label, Two-Part, Dose-Escalation Study of RAD1901 in Post-Menopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
17-595 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF PF-06863135, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)  (View details on clinicaltrial.gov) Phase I
16-274 A Phase I, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection to patients with advanced/metastatic solid tumors or lymphomas  (View details on clinicaltrial.gov) Phase I
15-129 A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands  (View details on clinicaltrial.gov) Phase I
15-502 A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase II
12-537 A Phase I/IB Study of Ipilimumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation  (View details on clinicaltrial.gov) Phase I
16-139 A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy  (View details on clinicaltrial.gov) Phase I
15-542 A Phase I/II Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas  (View details on clinicaltrial.gov) Phase II
15-055 A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients with Advanced, ALK-Positive, Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-464 A Phase I/II, Multicenter, Open-label Study of FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression  (View details on clinicaltrial.gov) Phase II
17-477 A Phase Ia/Ib, Multicenter, Open-label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-283 A Phase IB Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase I
15-346 A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers  (View details on clinicaltrial.gov) Phase II
13-313 A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
16-425 A Phase Ib/II Rescue Study With Azacitidine, Durvalumab (MEDI4736), and Tremelimumab Combination Therapy in Recurrent or Metastatic SCCHN Subjects Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy  (View details on clinicaltrial.gov) Phase II
17-112 A Phase IB/II Study of Alectinib Combined with Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC  (View details on clinicaltrial.gov) Phase II
13-367 A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-454 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors  (View details on clinicaltrial.gov) Phase II
16-104 A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)  (View details on clinicaltrial.gov) Phase II
15-448 A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma  (View details on clinicaltrial.gov) Phase II
14-328 A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy  (View details on clinicaltrial.gov) Phase II
15-012 A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, To Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations  (View details on clinicaltrial.gov) Phase II
17-365 A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity  (View details on clinicaltrial.gov) Phase II
17-269 A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma  (View details on clinicaltrial.gov) Phase II
16-118 A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
16-264 A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation of pCDC2 as a Biomarker of Target Response  (View details on clinicaltrial.gov) Phase II
17-264 A phase II study of core needle biopsy and cryoablation of an enlarging tumor in patients with metastatic advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibitor therapy  (View details on clinicaltrial.gov) Phase II
15-475 A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
17-011 A Phase II Study of Nivolumab in Combination with Carboplatin and Pemetrexed, or Nivolumab in Combination with Ipilimumab, in Patients with Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
16-293 A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer  (View details on clinicaltrial.gov) Phase II
10-308 A Phase II Study Of Proton Beam Therapy For Locally Advanced Sinonasal Malignancies  (View details on clinicaltrial.gov) Phase II
16-072 A Phase II Study of Ramucirumab in Patients with Advanced, Progressive Carcinoid Tumors  (View details on clinicaltrial.gov) Phase II
16-527 A Phase II Study of TAK-228 in Patients with Previously Treated Metastatic Renal Cell Carcinoma  (View details on clinicaltrial.gov) Phase II
16-642 A phase II trial of abbreviated MAPK targeted therapy plus pembrolizumab in patients with unresectable or metastatic melanoma  (View details on clinicaltrial.gov) Phase II
17-517 A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer  (View details on clinicaltrial.gov) Phase II
14-370 A Phase II Trial of Integrating Stereotactic Body Radiation Therapy with Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
17-090 A phase II trial of MGCD516, a multi-receptor tyrosine kinase inhibitor, in advanced liposarcoma and other soft tissue sarcomas  (View details on clinicaltrial.gov) Phase II
16-609 A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma  (View details on clinicaltrial.gov) Phase II
04-188 A Phase II Trial of Proton Radiation for the Treatment of Pediatric Rhabdomyosarcoma  (View details on clinicaltrial.gov) Phase II
17-169 A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy  (View details on clinicaltrial.gov) Phase II
15-387 A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase II
15-512 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma  (View details on clinicaltrial.gov) Phase II
17-603 A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment  (View details on clinicaltrial.gov) Phase II
16-649 A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
17-309 A phase II, open-label, single arm, multicenter study of Avelumab with hypofractionated re-irradiation in adult subjects with transformed IDH mutant glioblastoma  (View details on clinicaltrial.gov) Phase II
14-126 A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib.  (View details on clinicaltrial.gov) Phase II
14-029 A Phase II, Two-Tier study evaluating the efficacy and safety of Selinexor (KPT-330)in patients with recurrent Glioblastoma after failure of Radiation Thearpy and Temozolomide  (View details on clinicaltrial.gov) Phase II
16-707 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation  (View details on clinicaltrial.gov) Phase III
17-431 A Phase I-II Multicenter, Open Label Trial of H3B-6545, A Covalent Antagonist of Estrogen Receptor Alpha, in Women with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2 Negative Breast Cancer  (View details on clinicaltrial.gov) Phase II
17-413 A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)  (View details on clinicaltrial.gov) Phase III
17-151 A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)  (View details on clinicaltrial.gov) Phase III
15-719 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid  (View details on clinicaltrial.gov) Phase III
17-211 A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)  (View details on clinicaltrial.gov) Phase III
17-182 A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Enzalutamide versus Enzalutamide Alone in Patients with Metastatic Castration-Resistance Prostate Cancer after Failure of an Androgen Synthesis Inhibitor and Failure Of, Ineligibility For, or Refusal of a Taxane Regimen  (View details on clinicaltrial.gov) Phase III
17-511 A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  (View details on clinicaltrial.gov) Phase III
15-331 A Phase III, Open-label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation As Adjuvant Therapy in Patients with PD-L1-Selected, High-risk Muscle-Invasive Bladder Cancer After Cystecomy  (View details on clinicaltrial.gov) Phase III
15-191 A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy  (View details on clinicaltrial.gov) Phase III
17-117 A Phase lb, open-label, multicenter study of oral LXH254 in combination with oral L TT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
17-355 A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid hemangioendothelioma (EHE)  (View details on clinicaltrial.gov) Phase II
12-436 A Pilot Safety Study of Vaccination with Autologous, Lethally Irradiated Colorectal Cancer cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor in patients with Stage IV colorectal cancer  (View details on clinicaltrial.gov) N/A
17-311 A pilot study of FOLFIRINOX in combination with neoadjuvant radiation for gastric and GE junction cancers  (View details on clinicaltrial.gov) N/A
14-421 A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated with Chemoradiation or Immunotherapy  (View details on clinicaltrial.gov) N/A
18-705 A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma  (View details on clinicaltrial.gov) Phase II
16-256 A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase II
17-735 A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy  (View details on clinicaltrial.gov) Phase II
17-723 A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma  (View details on clinicaltrial.gov) Phase II
16-552 A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma  (View details on clinicaltrial.gov) Phase III
16-551 A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma  (View details on clinicaltrial.gov) Phase II
17-135 A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)  (View details on clinicaltrial.gov) Phase III
16-577 A Randomized Phase II Study of Eribulin Mesylate With or Without Pembrolizumab for Metastatic Hormone Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations  (View details on clinicaltrial.gov) Phase II
12-217 A randomized placebo-controlled phase II trial of irradiated, adenovirus vector transfected GM-CSF secreting autologous leukemia cell vaccination (GVAX) versus placebo vaccination in patients with advanced MDS/AML after allogeneic hematopoietic stem cell transplantation  (View details on clinicaltrial.gov) Phase II
17-395 A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy  (View details on clinicaltrial.gov) Phase III
16-244 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy  (View details on clinicaltrial.gov) Phase III
17-120 A Randomized, Double-blind, Placebo-controlled Phase III Study of ODM-201 versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer  (View details on clinicaltrial.gov) Phase III
16-197 A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer  (View details on clinicaltrial.gov) Phase III
15-030 A Randomized, Multi-center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease  (View details on clinicaltrial.gov) Phase III
16-563 A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation  (View details on clinicaltrial.gov) Phase II
14-375 A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
17-035 A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease  (View details on clinicaltrial.gov) Phase II
17-376 A Single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy  (View details on clinicaltrial.gov) Phase II
17-007 A single-arm, phase II study of neoadjuvant MPDL3280A, nab-paclitaxel and carboplatin (MAC) in resectable non-small cell lung cancer  (View details on clinicaltrial.gov) Phase II
17-458 A Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash (“Magic Mouthwash”) for the Management of Oral Mucositis Associated with High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients  (View details on clinicaltrial.gov) N/A
15-596 A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase II
17-557 A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease  (View details on clinicaltrial.gov) Phase II
13-322 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using [11C]Temozolomide PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
13-482 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using FMISO PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
17-300 A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)  (View details on clinicaltrial.gov) Phase II
16-265 A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy  (View details on clinicaltrial.gov) Phase I
16-509 A Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma, or Alveolar Rhabdomyosarcoma  (View details on clinicaltrial.gov) Phase II
15-701 A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase III
18-701 A091401: Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma  (View details on clinicaltrial.gov) Phase II
15-700 A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)  (View details on clinicaltrial.gov) N/A
16-717 AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov) Phase II
14-233 Adcetris (Brentuximab Vedotin) Substitution Vincristine in the OEPA/COPDAC Regimen [Treatment Group 3 (TG3 of Euro-Net C1] with Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
16-723 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)- A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers  (View details on clinicaltrial.gov) Phase III
11-464 Afatinib Sequenced with Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.  (View details on clinicaltrial.gov) Phase II
17-711 AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors  (View details on clinicaltrial.gov) Phase III
17-578 An Expanded Access Protocol For Lorlatinib For Treatment Of Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations  (View details on clinicaltrial.gov) N/A
17-585 An Exploratory Phase 1/2 Trial to Evaluation the Safety and Efficacy of JCAR017 Combination in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM)  (View details on clinicaltrial.gov) Phase II
17-495 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments  (View details on clinicaltrial.gov) Phase III
16-370 An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer  (View details on clinicaltrial.gov) Phase II
13-505 An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS Mutation-Positive Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-403 An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
17-180 An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer  (View details on clinicaltrial.gov) Phase I
17-218 An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non–Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
17-601 An open-label phase 1b clinical study of intravenous Cavatak ® (COXSACKIEVIRUS A21, CVA21), in combination with Ipilimumab in subjects with uveal melanoma metastatic to liver  (View details on clinicaltrial.gov) Phase I
16-212 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
17-032 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-690 An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant  (View details on clinicaltrial.gov) N/A
17-554 An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffman-LaRoche LTD Sponsored Atezolizimab Study  (View details on clinicaltrial.gov) N/A
15-212 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy  (View details on clinicaltrial.gov) Phase I
16-326 An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia  (View details on clinicaltrial.gov) Phase I
16-437 An Open-label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (Anti−pd-l1 Antibody) Administered in Combination with Bevacizumab and/or Other Treatments in Patients With Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-435 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2)  (View details on clinicaltrial.gov) Phase II
17-153 An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients with Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Failed Standard Treatments  (View details on clinicaltrial.gov) Phase I
17-251 An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-545 An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)  (View details on clinicaltrial.gov) Phase I
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
11-010 An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
16-344 An Open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder  (View details on clinicaltrial.gov) Phase I
15-530 An Open-label, Phase Ib/II Clinical Trial of CDK 4/6 Inhibitor, Ribociclib (LEE011), in Combination with Trastuzumab or TDM-1 for Advanced/Metastatic HER2-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-487 An Open-Label, Phase II Study to Determine the Immunologic Correlates of Pembrolizumab (MK-3475)-Mediated Tumor Regression in Subjects with Advanced Melanoma (KEYNOTE-161)  (View details on clinicaltrial.gov) Phase II
16-352 An open-label, pilot study of combination therapy with dabrafenib (GSK2118463) and trametinib (GSK1120212) in patients with relapsed multiple myeloma  (View details on clinicaltrial.gov) N/A
17-666 An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients  (View details on clinicaltrial.gov) N/A
16-721 ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)  (View details on clinicaltrial.gov) Phase III
12-188 BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on clinicaltrial.gov) Phase III
13-453 BMT CTN 1102: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome  (View details on clinicaltrial.gov) Phase III
12-134 CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide  (View details on clinicaltrial.gov) Phase III
08-207 Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on clinicaltrial.gov) N/A
17-336 Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies  (View details on clinicaltrial.gov) N/A
12-389 COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)  (View details on clinicaltrial.gov) Phase II
09-379 COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma  (View details on clinicaltrial.gov) Phase III
14-449 COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma  (View details on clinicaltrial.gov) Phase III
10-239 COG-ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years  (View details on clinicaltrial.gov) Phase III
16-616 Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers  (View details on clinicaltrial.gov) Phase II
17-283 Craniospinal Irradiation using Proton Beam Scanning with Selective Vertebral Body/Bone Sparing to Improve Marrow Reserve and Decrease Growth Decrement for Children  (View details on clinicaltrial.gov) N/A
16-406 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)  (View details on clinicaltrial.gov) N/A
14-037 Dose reduction of preoperative radiotherapy in myxoid liposarcoma  (View details on clinicaltrial.gov) Phase II
15-709 E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults  (View details on clinicaltrial.gov) Phase III
15-702 E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein  (View details on clinicaltrial.gov) Phase III
17-704 ECOG-ACRIN EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)  (View details on clinicaltrial.gov) Phase III
17-646 ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias  (View details on clinicaltrial.gov) Phase III
16-612 Evaluating the expression levels of microRNA-10b in patients with Gliomas  (View details on clinicaltrial.gov) N/A
12-307 Evaluation of PET/MRI in Children with Cancer  (View details on clinicaltrial.gov) N/A
17-422 Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation  (View details on clinicaltrial.gov) N/A
16-195 Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with ER-positive, HER2-negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase II
12-452 GOG-0279:Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC#613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva  (View details on clinicaltrial.gov) Phase II
17-208 GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease  (View details on clinicaltrial.gov) Phase III
10-218 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma  (View details on clinicaltrial.gov) Phase II
09-273 HOD08: Reduced Duration Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
16-443 Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  (View details on clinicaltrial.gov) Phase II
13-428 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis  (View details on clinicaltrial.gov) Phase III
17-250 Local Control, Quality of Life and Toxicities in Adults with Benign or Indolent Brain Tumors undergoing Proton Radiation Therapy  (View details on clinicaltrial.gov) N/A
17-425 Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)  (View details on clinicaltrial.gov) N/A
16-750 Molecular Analysis for Therapy Choice (MATCH)  (View details on clinicaltrial.gov) Phase II
12-023 NCCTG-N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision  (View details on clinicaltrial.gov) Phase III
17-021 Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
15-423 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS- 936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors  (View details on clinicaltrial.gov) Phase II
13-195 Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial  (View details on clinicaltrial.gov) Phase II
15-708 NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-710 NRG-GI001: Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma  (View details on clinicaltrial.gov) Phase III
17-733 NRG-GI003: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase III
17-754 NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA  (View details on clinicaltrial.gov) Phase III
12-466 Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on clinicaltrial.gov) Phase II
16-542 Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy  (View details on clinicaltrial.gov) Phase III
17-261 Optimizing post-allogeneic hematopoietic cell transplant outcomes for lymphoma using ibrutinib  (View details on clinicaltrial.gov) Phase II
15-318 Oral ONC201 in Adult Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-488 PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase III
16-704 Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)  (View details on clinicaltrial.gov) Phase III
17-326 Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma with Molecular Correlates  (View details on clinicaltrial.gov) Phase II
16-538 Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10C796T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors  (View details on clinicaltrial.gov) Phase I
16-054 Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma and the Longterm Follow-up of Subjects Treated with bb2121  (View details on clinicaltrial.gov) Phase I
11-318 Phase 1, Multicenter, Open-label, Dose-escalation Study of ACE-011 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
18-061 PHASE 1, TWO-PART, MULTICENTER, NONRANDOMIZED, OPEN-LABEL, MULTIPLE DOSE, FIRST-IN-HUMAN STUDY OF DS-1062a IN SUBJECTS WITH ADVANCED SOLID TUMORS  (View details on clinicaltrial.gov) Phase I
16-150 Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers  (View details on clinicaltrial.gov) Phase I
16-501 Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase II
18-706 Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-436 Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
16-210 Phase 1b Study to Assess The Safety, Tolerability, And Clinical Activity of Gedatolisib In Combination With Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)  (View details on clinicaltrial.gov) Phase I
17-293 Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome  (View details on clinicaltrial.gov) Phase I
15-479 Phase 1b/2, Open-label, Dose-finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of Avelumab (msb0010718c) in Combination with Either Crizotinib or Pf-06463922 in Patients with Advanced or Metastatic Non-small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
16-574 Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) plus Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia  (View details on clinicaltrial.gov) Phase II
16-724 Phase 2 Study of VX-970 (NSC# 780162) in Combination with gemcitabine versus gemcitabine alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer  (View details on clinicaltrial.gov) Phase II
16-589 Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase II
17-107 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase III
14-213 Phase I Dose Escalation Study of Velcade in Combination with Lenalidomide in Patients with Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase I
14-186 Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-200 Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults  (View details on clinicaltrial.gov) Phase I
13-115 Phase I Study of Olaparib and Temozolomide in Adult Patients with Recurrent/Metastatic Ewing's Sarcoma following failure of prior chemotherapy  (View details on clinicaltrial.gov) Phase I
16-464 Phase I study of Regorafenib in Patients with Advanced Myeloid Malignancies  (View details on clinicaltrial.gov) Phase I
16-004 Phase I, Multicenter, Open-Label, Clinical and Pharmacokinetics Study of PM01183 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-399 Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL) CALM study (UCART19 in Advanced Lymphoid Malignancies)  (View details on clinicaltrial.gov) Phase I
12-100 Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas  (View details on clinicaltrial.gov) Phase II
15-024 Phase Ib dose-escalation trial of Taselisib (GDC-0032) in combination with anti-HER2 therapies in participants with advanced HER2+ Breast Cancer  (View details on clinicaltrial.gov) Phase I
17-383 Phase Ib Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma  (View details on clinicaltrial.gov) Phase I
16-423 Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)  (View details on clinicaltrial.gov) Phase I
17-231 Phase Ib/II Study of TAS-102 plus radiation therapy for the treatment of the liver in patients with hepatic metastases from colorectal cancer  (View details on clinicaltrial.gov) Phase II
17-037 Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
14-056-RISK Phase II Double-Blind Randomized Controlled Trial of Naltrexone for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-169 Phase II Multicenter Study of Natalizumab Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease  (View details on clinicaltrial.gov) Phase II
17-232 Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in combination with Adjuvant endocrine therapy at varying Duration for ER-positive Breast Cancer (LEADER)  (View details on clinicaltrial.gov) Phase II
15-005 Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis  (View details on clinicaltrial.gov) Phase II
17-273 Phase II Study of Maintenance Ruxolitinib after Allogeneic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)  (View details on clinicaltrial.gov) Phase II
13-443 Phase II Study of Proton Radiation Therapy for Neuroblastoma  (View details on clinicaltrial.gov) Phase II
12-456 Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors  (View details on clinicaltrial.gov) Phase II
17-722 Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas  (View details on clinicaltrial.gov) Phase II
13-249 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults  (View details on clinicaltrial.gov) Phase II
16-136 Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases  (View details on clinicaltrial.gov) Phase II
14-140 Phase II Trial of Natalizumab (Tysabri) plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract  (View details on clinicaltrial.gov) Phase II
16-254 Phase II Trial of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway  (View details on clinicaltrial.gov) Phase II
16-153 Phase II Trial of Pembrolizumab in Central Nervous System Metastases from Multiple Histologies  (View details on clinicaltrial.gov) Phase II
17-296 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma  (View details on clinicaltrial.gov) Phase II
17-233 Phase II trial of Ribociclib in combination with Everolimus in advanced dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS)  (View details on clinicaltrial.gov) Phase II
16-155 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the treatment of Oropharyngeal Cancer of the Head and Neck  (View details on clinicaltrial.gov) Phase III
16-386 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinumcontaining Line (ATLANTIS Trial)  (View details on clinicaltrial.gov) Phase III
11-497 Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on clinicaltrial.gov) Phase III
10-269 Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes  (View details on clinicaltrial.gov) N/A
14-333 Pilot Study of EGFR Inhibition with Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma  (View details on clinicaltrial.gov) N/A
17-416 Pilot Study of Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning  (View details on clinicaltrial.gov) N/A
17-305 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study  (View details on clinicaltrial.gov) N/A
16-188 Pragmatic Phase III Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  (View details on clinicaltrial.gov) Phase III
16-728 Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme  (View details on clinicaltrial.gov) Phase II
15-185 Randomized Phase II Study Comparing Selumetinib to Placebo for Enhancing the Clinical Efficacy of Radioactive Iodine (RAI) for RAI-Avid Recurrent/Metastatic Thyroid Cancers Uptake  (View details on clinicaltrial.gov) Phase II
16-705 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas  (View details on clinicaltrial.gov) Phase II
15-706 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma  (View details on clinicaltrial.gov) Phase II
15-287 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib  (View details on clinicaltrial.gov) Phase III
16-093 Rapid plasma genotyping for early initiation of erlotinib in EGFR mutant lung cancer  (View details on clinicaltrial.gov) Phase II
09-042 RRP450 - Phase I Trial in Liver Metastases and Primary Liver Tumors  (View details on clinicaltrial.gov) Phase I
14-268 RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC  (View details on clinicaltrial.gov) Phase III
15-469 Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients with Laryngeal, Tracheal and/or Pulmonary Involvement  (View details on clinicaltrial.gov) Phase II
14-416 SWOG 1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (LUNG-MAP)  (View details on clinicaltrial.gov) Phase III
16-320 TRINITI-1: A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor  (View details on clinicaltrial.gov) Phase I
354 clinical trials listed

Back to Top